1. Scrip
  2. >>Business
  3. >>Strategy

France’s Enterome Eyes Merger To Make NASDAQ Move

As IBD Pact Is Signed With Nestlé

 
• By Kevin Grogan

CEO Pierre Belichard tells Scrip that the French biotech has enough cash and assets to prosper alone but it is also weighing up a reverse merger that would give Enterome a listing on the NASDAQ.

NASDAQ
Enterome plots path to Wall Street • Source: Shutterstock

Having inked another deal with Nestle Health Science, microbiome specialist Enterome Bioscience is now weighing up potential merger partners that would give the privately held French firm a listing in the US.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business